KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash & Equivalents (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Cash & Equivalents for 9 consecutive years, with $201000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 4.29% year-over-year to $201000.0, compared with a TTM value of $201000.0 through Dec 2025, down 4.29%, and an annual FY2025 reading of $201000.0, down 4.29% over the prior year.
  • Cash & Equivalents was $201000.0 for Q4 2025 at Biocryst Pharmaceuticals, down from $84.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $110.6 million in Q4 2023 and bottomed at $201000.0 in Q4 2025.
  • Average Cash & Equivalents over 3 years is $33.8 million, with a median of $1.7 million recorded in 2023.
  • Peak annual rise in Cash & Equivalents hit 6013.7% in 2024, while the deepest fall reached 99.81% in 2024.
  • Year by year, Cash & Equivalents stood at $110.6 million in 2023, then crashed by 99.81% to $210000.0 in 2024, then decreased by 4.29% to $201000.0 in 2025.
  • Business Quant data shows Cash & Equivalents for BCRX at $201000.0 in Q4 2025, $84.1 million in Q3 2025, and $492000.0 in Q2 2025.